173,458 Shares in Guardian Pharmacy Services, Inc. $GRDN Acquired by Ranger Investment Management L.P.

Key Points

• Ranger Investment Management acquired 173,458 Guardian Pharmacy Services shares worth approximately $7.3 million, representing about 0.35% of the company.
• Analyst sentiment remains positive: eight analysts rate GRDN a Buy and one rates it Hold, with a consensus “Moderate Buy” rating and an average price target of $43.83.
• Guardian Pharmacy reported quarterly EPS of $0.29, beating estimates of $0.26, while revenue reached $351.77 million versus the $340.45 million consensus estimate.

Ranger Investment Management L.P. acquired a new stake in Guardian Pharmacy Services, Inc. (NYSE:GRDN - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 173,458 shares of the company's stock, valued at approximately $7,263,000. Ranger Investment Management L.P. owned approximately 0.35% of Guardian Pharmacy Services at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. lifted its holdings in shares of Guardian Pharmacy Services by 26.5% during the third quarter. Ameritas Investment Partners Inc. now owns 1,647 shares of the company's stock worth $43,000 after buying an additional 345 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of Guardian Pharmacy Services by 3.4% in the fourth quarter. California State Teachers Retirement System now owns 17,983 shares of the company's stock valued at $541,000 after acquiring an additional 593 shares during the period. Police & Firemen s Retirement System of New Jersey grew its stake in shares of Guardian Pharmacy Services by 20.4% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 6,070 shares of the company's stock valued at $183,000 after acquiring an additional 1,028 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Guardian Pharmacy Services by 13.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 11,885 shares of the company's stock valued at $358,000 after acquiring an additional 1,409 shares in the last quarter. Finally, Clearstead Advisors LLC increased its position in Guardian Pharmacy Services by 196.3% during the fourth quarter. Clearstead Advisors LLC now owns 2,628 shares of the company's stock worth $79,000 after acquiring an additional 1,741 shares during the period.

Analyst Upgrades and Downgrades

Several analysts have weighed in on GRDN shares. Zacks Research cut shares of Guardian Pharmacy Services from a "strong-buy" rating to a "hold" rating in a research note on Monday, May 11th. Truist Financial increased their target price on shares of Guardian Pharmacy Services from $43.00 to $47.00 and gave the stock a "buy" rating in a research report on Wednesday, June 17th. Weiss Ratings raised shares of Guardian Pharmacy Services from a "hold (c+)" rating to a "buy (b-)" rating in a report on Thursday. Oppenheimer lifted their price target on shares of Guardian Pharmacy Services from $43.00 to $49.00 and gave the company an "outperform" rating in a research report on Friday, August 7th. Finally, Bank of America boosted their price target on Guardian Pharmacy Services from $42.00 to $47.00 and gave the company a "buy" rating in a research note on Wednesday, June 17th. Eight investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $43.83.

Guardian Pharmacy Services Stock Down 0.1%

GRDN stock opened at $37.90 on Monday. Guardian Pharmacy Services, Inc. has a 52 week low of $23.14 and a 52 week high of $47.02. The business has a 50-day simple moving average of $40.44 and a 200 day simple moving average of $37.75. The company has a market cap of $1.89 billion, a PE ratio of 36.80, a price-to-earnings-growth ratio of 1.96 and a beta of 0.11.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.26 by $0.03. The firm had revenue of $351.77 million for the quarter, compared to the consensus estimate of $340.45 million. Guardian Pharmacy Services had a net margin of 4.50% and a return on equity of 29.97%. On average, analysts anticipate that Guardian Pharmacy Services, Inc. will post 1.19 EPS for the current fiscal year.

Guardian Pharmacy Services Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.

Want to see what other hedge funds are holding GRDN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardian Pharmacy Services, Inc. (NYSE:GRDN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source